NO20091057L - Oral form of birth control - Google Patents
Oral form of birth controlInfo
- Publication number
- NO20091057L NO20091057L NO20091057A NO20091057A NO20091057L NO 20091057 L NO20091057 L NO 20091057L NO 20091057 A NO20091057 A NO 20091057A NO 20091057 A NO20091057 A NO 20091057A NO 20091057 L NO20091057 L NO 20091057L
- Authority
- NO
- Norway
- Prior art keywords
- birth control
- dienogest
- oral form
- less
- daily dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
Oral legemiddelform for prevensjon omfatter som en aktiv forbindelse, 17a-cyanometyl-17-ß-hydroksyøstra-4,9-dien-3-on (dienogest) i en daglig dose lik eller mindre enn 2,0 mg og som annen aktiv komponent 17a-etynyløstradiol (etynyløstradiol) i en daglig dose på mindre enn 0,03 mg, sammen med én eller flere farmasøytisk akseptable bærere. Den aktive bestanddel dienogest er til stede i krystallinsk form med en midlere partikkelstørrelse på fra 25 til 70 µm. Den aktive bestanddel etynyløstradiol er innført i mikronisert form eller som etanolisk løsning under granuleringen.Oral form of birth control comprises, as an active compound, 17α-cyanomethyl-17-β-hydroxyester-4,9-dien-3-one (dienogest) in a daily dose equal to or less than 2.0 mg and as another active component 17a -ethynyl estradiol (ethynyl estradiol) at a daily dose of less than 0.03 mg, together with one or more pharmaceutically acceptable carriers. The active ingredient dienogest is present in crystalline form with an average particle size of from 25 to 70 µm. The active ingredient ethynyl oestradiol is introduced in micronized form or as ethanolic solution during the granulation.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06016694A EP1886694B1 (en) | 2006-08-10 | 2006-08-10 | Peroral formulation of dienogest and ethinylestradiol for contraception |
| PCT/EP2007/003662 WO2008017331A2 (en) | 2006-08-10 | 2007-04-26 | Peroral drug form comprising dienogest and ethinyl estradiol for contraception |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20091057L true NO20091057L (en) | 2009-03-09 |
Family
ID=37561777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20091057A NO20091057L (en) | 2006-08-10 | 2009-03-09 | Oral form of birth control |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1886694B1 (en) |
| AR (1) | AR062323A1 (en) |
| AT (1) | ATE432714T1 (en) |
| CL (1) | CL2007002323A1 (en) |
| CY (1) | CY1110348T1 (en) |
| DE (1) | DE502006003892D1 (en) |
| DK (1) | DK1886694T3 (en) |
| DO (1) | DOP2007000122A (en) |
| ES (1) | ES2327665T3 (en) |
| HR (1) | HRP20090438T1 (en) |
| NO (1) | NO20091057L (en) |
| PE (1) | PE20080541A1 (en) |
| PL (1) | PL1886694T3 (en) |
| PT (1) | PT1886694E (en) |
| SI (1) | SI1886694T1 (en) |
| TW (1) | TW200817012A (en) |
| UY (1) | UY30530A1 (en) |
| WO (1) | WO2008017331A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010003711B4 (en) | 2010-04-08 | 2015-04-09 | Jesalis Pharma Gmbh | Process for the preparation of crystalline active substance particles |
| CN115487198B (en) * | 2022-09-20 | 2024-01-02 | 华中药业股份有限公司 | Levonorgestrel preparation with fast dissolution rate and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1216713A1 (en) * | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
| DE10218107A1 (en) * | 2002-04-23 | 2003-11-20 | Jenapharm Gmbh | Process for the production of crystals of steroids, crystals available thereafter and their use in pharmaceutical formulations |
-
2006
- 2006-08-10 PL PL06016694T patent/PL1886694T3/en unknown
- 2006-08-10 ES ES06016694T patent/ES2327665T3/en active Active
- 2006-08-10 EP EP06016694A patent/EP1886694B1/en active Active
- 2006-08-10 AT AT06016694T patent/ATE432714T1/en active
- 2006-08-10 DK DK06016694T patent/DK1886694T3/en active
- 2006-08-10 PT PT06016694T patent/PT1886694E/en unknown
- 2006-08-10 DE DE502006003892T patent/DE502006003892D1/en active Active
- 2006-08-10 SI SI200630376T patent/SI1886694T1/en unknown
-
2007
- 2007-04-26 WO PCT/EP2007/003662 patent/WO2008017331A2/en active Application Filing
- 2007-07-16 TW TW096125903A patent/TW200817012A/en unknown
- 2007-08-07 UY UY30530A patent/UY30530A1/en unknown
- 2007-08-09 PE PE2007001064A patent/PE20080541A1/en not_active Application Discontinuation
- 2007-08-09 DO DO2007000122A patent/DOP2007000122A/en unknown
- 2007-08-09 CL CL200702323A patent/CL2007002323A1/en unknown
- 2007-08-10 AR ARP070103547A patent/AR062323A1/en not_active Application Discontinuation
-
2009
- 2009-03-09 NO NO20091057A patent/NO20091057L/en not_active Application Discontinuation
- 2009-08-13 HR HR20090438T patent/HRP20090438T1/en unknown
- 2009-09-03 CY CY20091100928T patent/CY1110348T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008017331A3 (en) | 2009-01-08 |
| DK1886694T3 (en) | 2009-09-28 |
| TW200817012A (en) | 2008-04-16 |
| PL1886694T3 (en) | 2009-11-30 |
| CY1110348T1 (en) | 2015-04-29 |
| UY30530A1 (en) | 2008-03-31 |
| WO2008017331A2 (en) | 2008-02-14 |
| DOP2007000122A (en) | 2008-02-15 |
| AR062323A1 (en) | 2008-10-29 |
| HRP20090438T1 (en) | 2009-09-30 |
| ATE432714T1 (en) | 2009-06-15 |
| SI1886694T1 (en) | 2009-10-31 |
| CL2007002323A1 (en) | 2008-02-15 |
| PE20080541A1 (en) | 2008-07-10 |
| EP1886694B1 (en) | 2009-06-03 |
| PT1886694E (en) | 2009-08-17 |
| EP1886694A1 (en) | 2008-02-13 |
| ES2327665T3 (en) | 2009-11-02 |
| DE502006003892D1 (en) | 2009-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540482A5 (en) | ||
| MX2008011074A (en) | Extended cycle multiphasic oral contraceptive method. | |
| JP2007535519A5 (en) | ||
| NZ605176A (en) | Pharmaceutical composition comprising drospirenone and contraceptive kit | |
| NO20091954L (en) | Use of ostradiol valerate or 17β-ostradil in combination with dienogest for oral therapy to maintain and / or increase female libido | |
| WO2007021805A3 (en) | Estrogen compositions and therapeutic methods of use thereof | |
| KR20000022189A (en) | Progestogen-anti-progestogen regimens | |
| AR061959A1 (en) | PHARMACEUTICAL COMPOSITION FOR CONTRACEPTION AND TO REDUCE THE RISK OF CONGENITAL MALFORMATIONS | |
| NO20056153L (en) | Preparation comprising antiprogestins and pure antiostrogens for prophylaxis and treatment of hormone-dependent diseases | |
| WO2005092441A3 (en) | Extended cycle multiphasic oral contraceptive method | |
| NO20091057L (en) | Oral form of birth control | |
| HRP20080394T3 (en) | Peroral solid dosage form for contraception comprising dienogest and ethinylestradiol | |
| NO20072687L (en) | Pharmaceutical contraceptive preparation | |
| TW200731977A (en) | Use of estradiol valerate in combination with dienogest for the oral treatment of dysfunctional uterine bleeding in conjunction with oral contraception | |
| TN2009000263A1 (en) | Pharmaceutical preparation for the alleviation of endometriosis | |
| UY29378A1 (en) | PHARMACEUTICAL PREPARATION FOR ORAL ANTI-CONCEPTION | |
| PE20091020A1 (en) | USE OF A GESTAGEN IN COMBINATION WITH A ESTROGEN AND ONE OR MORE PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS / CARRIERS FOR LACTOSE-FREE ORAL CONTRACEPTION | |
| HRP20200155T1 (en) | Pharmaceutical composition comprising drospirenone and contraceptive kit | |
| TH80558B (en) | Solid oral dosage forms for birth control | |
| WO2007042111A3 (en) | Use of estradiol valerate combined with dienogest for oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives | |
| TH80558A (en) | Solid oral dosage forms for birth control | |
| RS50849B (en) | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method | |
| TH80557B (en) | Pharmaceutical products for oral contraception | |
| RU2009135418A (en) | SINGLE PHASE PHARMACEUTICAL COMPOSITE PRODUCT (DIENOGEST AND ETHINYLESTRADIOL) FOR ORAL THERAPY FOR REGULATION OF ARTERIAL PRESSURE | |
| RU2009140372A (en) | NEW MODE WITH DROSPIRENONE / 17B-ESTRADIOL, PHARMACEUTICAL COMBINED PRODUCT AND KIT FOR THE PERFORMANCE OF THIS MODE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |